- Home
- GOSS vs INMB Comparison
GOSS vs INMB Comparison
Compare GOSS & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- INMB
- Stock Information
- Founded
- GOSS 2015
- INMB 2015
- Country
- GOSS United States
- INMB United States
- Employees
- GOSS N/A
- INMB N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- GOSS Health Care
- INMB Health Care
- Exchange
- GOSS Nasdaq
- INMB Nasdaq
- Market Cap
- GOSS 203.3M
- INMB 176.5M
- IPO Year
- GOSS 2019
- INMB 2019
- Fundamental
- Price
- GOSS $1.16
- INMB $7.47
- Analyst Decision
- GOSS Strong Buy
- INMB Strong Buy
- Analyst Count
- GOSS 4
- INMB 3
- Target Price
- GOSS $7.75
- INMB $24.33
- AVG Volume (30 Days)
- GOSS 1.6M
- INMB 274.4K
- Earning Date
- GOSS 05-15-2025
- INMB 05-08-2025
- Dividend Yield
- GOSS N/A
- INMB N/A
- EPS Growth
- GOSS N/A
- INMB N/A
- EPS
- GOSS N/A
- INMB N/A
- Revenue
- GOSS $124,590,000.00
- INMB $50,000.00
- Revenue This Year
- GOSS N/A
- INMB N/A
- Revenue Next Year
- GOSS $190.37
- INMB $43,178.43
- P/E Ratio
- GOSS N/A
- INMB N/A
- Revenue Growth
- GOSS N/A
- INMB N/A
- 52 Week Low
- GOSS $0.50
- INMB $4.32
- 52 Week High
- GOSS $1.55
- INMB $10.50
- Technical
- Relative Strength Index (RSI)
- GOSS 55.35
- INMB 48.52
- Support Level
- GOSS $1.09
- INMB $7.15
- Resistance Level
- GOSS $1.20
- INMB $8.06
- Average True Range (ATR)
- GOSS 0.09
- INMB 0.45
- MACD
- GOSS 0.00
- INMB -0.01
- Stochastic Oscillator
- GOSS 69.01
- INMB 27.62
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.